The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Primary Vitreoretinal Lymphoma: A Report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium
Open accessAbstract
Primary vitreoretinal lymphoma (PVRL), also known as primary intraocular lymphoma, is a rare malignancy typically classified as a diffuse large B-cell lymphoma and most frequently develops in elderly populations. PVRL commonly masquerades as posterior uveitis and has a unique tropism for the retina and central nervous system (CNS). Over 15% of primary CNS lymphoma patients develop intraocular lymphoma, usually occurring in the retina and/or vitreous. Conversely, 65%–90% of PVRL patients develop CNS lymphoma. Consequently, PVRL is often fatal because of ultimate CNS association. Current PVRL animal models are limited and require further development. Typical clinical findings include vitreous cellular infiltration (lymphoma and inflammatory cells) and subretinal tumor infiltration as determined using dilated fundoscopy, fluorescent angiography, and optical coherent tomography. Currently, PVRL is most often diagnosed using both histology to identify lymphoma cells in the vitreous or retina and immunohistochemistry to indicate monoclonality. Additional adjuncts in diagnosing PVRL exist, including elevation of interleukin-10 levels in ocular fluids and detection of IgH or T-cell receptor gene rearrangements in malignant cells. The optimal therapy for PVRL is not defined and requires the combined effort of oncologists and ophthalmologists. PVRL is sensitive to radiation therapy and exhibits high responsiveness to intravitreal methotrexate or rituximab. Although systemic chemotherapy alone can result in high response rates in patients with PVRL, there is a high relapse rate. Because of the disease rarity, international, multicenter, collaborative efforts are required to better understand the biology and pathogenesis of PVRL as well as to define both diagnostic markers and optimal therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Dolecek, T. A., Propp, J. M., Stroup, N. E., & Kruchko, C. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos218 · Cited by 1,710
Primary central nervous system lymphoma
Hochberg, F. H., & Miller, D. C. (1988) · Journal of neurosurgery · doi:10.3171/jns.1988.68.6.0835 · Cited by 821
Batchelor, T., Carson, K., O’Neill, A., Grossman, S. A., Alavi, J., New, P., Hochberg, F., & Priet, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.036 · Cited by 546
Self-citationCXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity.
Ansel, K. M., Harris, R. B. S., & Cyster, J. G. (2002) · Immunity · doi:10.1016/s1074-7613(01)00257-6 · Cited by 449
Surawicz, T. S., McCarthy, B. J., Kupelian, V. A., Jukich, P. J., Bruner, J. M., & Davis, F. G. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.1.14 · Cited by 443
Batchelor, T., & Loeffler, J. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8819 · Cited by 362
Self-citationSoussain, C., Hoang-Xuan, K., Taillandier, L., Fourme, E., Choquet, S., Witz, F., Casasnovas, O., Dupriez, B., Souleau, B., Taksin, A.-L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5533 · Cited by 324
Understanding intraocular lymphomas
Coupland, S. E., & Damato, B. (2008) · Clinical & Experimental Ophthalmology · doi:10.1111/j.1442-9071.2008.01843.x · Cited by 313
Self-citationThe miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition
Cloonan, N., Brown, M. K., Steptoe, A. L., Wani, S., Chan, W. L., Forrest, A. R., Kolle, G., Gabrielli, B., & Grimmond, S. M. (2008) · Genome Biology · doi:10.1186/gb-2008-9-8-r127 · Cited by 304
Complications of intravitreal injections
Sampat, K. M., & Garg, S. J. (2010) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e328338679a · Cited by 287
Smith, J. (2002) · Ophthalmology · doi:10.1016/s0161-6420(02)01125-9 · Cited by 277
Self-citationIntravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience
Frenkel, S., Hendler, K., Siegal, T., Shalom, E., & Pe'er, J. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.127928 · Cited by 271
Central Nervous System Cancers
Nabors, L. B., Ammirati, M., Bierman, P. J., Brem, H., Butowski, N., Chamberlain, M. C., DeAngelis, L. M., Fenstermaker, R. A., Friedman, A., Gilbert, M. R., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0132 · Cited by 247
Intravitreal Methotrexate as an Adjunctive Treatment of Intraocular Lymphoma
Fishburne, B. C. (1997) · Archives of Ophthalmology · doi:10.1001/archopht.1997.01100160322009 · Cited by 217
Gene expression and angiotropism in primary CNS lymphoma
Rubenstein, J. L., Fridlyand, J., Shen, A., Aldape, K., Ginzinger, D., Batchelor, T., Treseler, P., Berger, M., McDermott, M., Prados, M., et al. (2006) · Blood · doi:10.1182/blood-2005-03-0897 · Cited by 210
Self-citationSmith, J. R., Braziel, R. M., Paoletti, S., Lipp, M., Uguccioni, M., & Rosenbaum, J. T. (2003) · Blood · doi:10.1182/blood-2002-05-1576 · Cited by 196
Self-citationIs Intrathecal Methotrexate Necessary in the Treatment of Primary CNS Lymphoma?
Khan, R. B., Shi, W., Thaler, H. T., DeAngelis, L. M., & Abrey, L. E. (2002) · Journal of Neuro-Oncology · doi:10.1023/a:1016077907952 · Cited by 186
Pathway analysis of primary central nervous system lymphoma
Tun, H. W., Personett, D., Baskerville, K. A., Menke, D. M., Jaeckle, K. A., Kreinest, P., Edenfield, B., Zubair, A. C., O'Neill, B. P., Lai, W. R., et al. (2008) · Blood · doi:10.1182/blood-2007-10-119099 · Cited by 166
Shen, D. F., Zhuang, Z., LeHoang, P., Böni, R., Zheng, S., Nussenblatt, R. B., & Chan, C.-C. (1998) · Ophthalmology · doi:10.1016/s0161-6420(98)99036-4 · Cited by 160
Self-citationProtein Biomarker Identification in the CSF of Patients With CNS Lymphoma
Roy, S., Josephson, S. A., Fridlyand, J., Karch, J., Kadoch, C., Karrim, J., Damon, L. E., TRESELER, P. A., Kunwar, S., Shuman, M. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1053 · Cited by 154
Self-citationIntravitreal chemotherapy for the treatment of recurrent intraocular lymphoma
de Smet, M. D., Vancs, V. S., Köhler, D., Solomon, D., & Chan, C. (1999) · British Journal of Ophthalmology · doi:10.1136/bjo.83.4.448 · Cited by 130
Self-citationChan, C., Shen, D., Hackett, J., Buggage, R. R., & Tuaillon, N. (2003) · Ophthalmology · doi:10.1016/s0161-6420(02)01737-2 · Cited by 115
Self-citationEpigenetics of Acute Lymphocytic Leukemia
Garcia‐Manero, G., Yang, H., Kuang, S.-Q., O'Brien, S. M., Thomas, D. A., & Kantarjian, H. M. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.09.008 · Cited by 97
Pathophysiology of Retinal Lymphoma
Coupland, S. E., Chan, C. C., & Smith, J. R. (2009) · Ocular Immunology and Inflammation · doi:10.1080/09273940903168696 · Cited by 90
Self-citationRobertus, J. L., Harms, G., Blokzijl, T., Booman, M., de Jong, D., Imhoff, G. W. V., Rosati, S., Schuuring, E. M. D., Kluin, P. M., & van den Berg, A. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.10 · Cited by 80
Wong, L. J., Desai, R. U., Jain, A., Feliciano, D. M., Moshfeghi, D. M., Sanislo, S. R., & Blumenkranz, M. S. (2008) · Retina · doi:10.1097/iae.0b013e31817e100f · Cited by 77
Bokstein, F., Lossos, A., Lossos, I. S., et al. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190290012092 · Cited by 67
Rituximab for Intraocular Lymphoma
Itty, S., & Pulido, J. S. (2009) · Retina · doi:10.1097/iae.0b013e318192f574 · Cited by 64
Self-citationMcCann, K. J., Ashton‐Key, M., Smith, K., Stevenson, F. K., & Ottensmeier, C. H. H. (2008) · Blood · doi:10.1182/blood-2008-09-179366 · Cited by 56
de Lima, L. H. S. G., Zweifel, S. A., Engelbert, M., Sorenson, J. A., Slakter, J. S., Cooney, M. J., Klancnik, J. M., Yannuzzi, L. A., & Freund, K. B. (2009) · Retina · doi:10.1097/iae.0b013e3181b32d27 · Cited by 56
Smith, J. R., Falkenhagen, K. M., Coupland, S. E., Chipps, T. J., Rosenbaum, J. T., & Braziel, R. M. (2007) · American Journal of Clinical Pathology · doi:10.1309/nuqhj79bhwyd9taf · Cited by 55
Self-citationDiagnosis of systemic metastatic retinal lymphoma
Cao, X., Shen, D., Callanan, D., Mochizuki, M., & Chan, C. (2009) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2009.01797.x · Cited by 53
Self-citationTHE SAFETY OF INTRAOCULAR METHOTREXATE IN SILICONE-FILLED EYES
Hardwig, P. W., Pulido, J. S., & Bakri, S. J. (2008) · Retina · doi:10.1097/iae.0b013e3181754231 · Cited by 48
Self-citationSurawicz, T. S. (1999) · Neuro-Oncology · doi:10.1215/15228517-1-1-14 · Cited by 46
Robertson, D. M. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.5.652 · Cited by 45
Entry routes of malignant lymphoma into the brain and eyes in a mouse model.
Hochman, J., Assaf, N., Deckert‐Schlüter, M., Wiestler, O. D., & Pe'er, J. (2001) · PubMed · Cited by 42
Minéo, J.-F., Scheffer, A., Karkoutly, C., Nouvel, L., Kerdraon, O., Trauet, J., Bordron, A., Dessaint, J., Labalette, M., Berthou, C., et al. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-1494 · Cited by 38
Touitou, V., Daussy, C., Bodaghi, B., Camelo, S., de Kozak, Y., LeHoang, P., Naud, M., Varin, A., Thillaye-Goldenberg, B., Merle‐Béral, H., et al. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0008 · Cited by 37
Self-citationVelez, G., Boldt, H. C., Whitcup, S. M., Nussenblatt, R. B., & Robinson, M. R. (2002) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/1542-8877-20020701-16 · Cited by 31
Trikha, R., Morse, L. S., Zawadzki, R. J., Werner, J. S., & Park, S. S. (2011) · Retina · doi:10.1097/iae.0b013e318203ee46 · Cited by 19
Cited by
Good News–Bad News: The Yin and Yang of Immune Privilege in the Eye
Forrester, J. V., & Xu, H. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00338 · Cited by 153
Metadata
- Authors
- Chan, C.-C., Rubenstein, J. L., Coupland, S. E., Davis, J. L., Harbour, J. W., Johnston, P. B., Cassoux, N., Touitou, V., Smith, J. R., Batchelor, T. T., & Pulido, J. S.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-11-01
- Volume
- 16
- Issue
- 11
- Pages
- 1589-1599
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W1983979831
- Cited by
- 486
- References
- 44
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.